Initial Trials Indicate Reduced Intensity Stem Cell Transplant Safe for Scleroderma Patients
American College of Rheumatology (ACR)A phase I trial of non-myeloablative or reduced intensity hematopoietic stem cell transplantation (HSCT) in patients with systemic sclerosis (scleroderma) has proven safe and well tolerated, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Washington, DC.